COVID-19 - June 2, 2021
Sanofi & GSK initiate Phase 3 study of their vaccine candidate
The global, randomized, double-blind placebo-controlled Phase 3 study will include more than 35,000 volunteers aged 18 and older from several countries, including sites in the US, Asia, Africa, and Latin America. The primary endpoint of the study is the prevention of symptomatic COVID-19 in SARS-CoV-2 naïve adults, with secondary endpoints being the prevention of severe […]
COVID-19 - June 2, 2021
New Finnish test detects coronavirus infection in 10 minutes
An antigen-based detection technique developed by University of Helsinki researchers could be used to analyze as many as 500 samples per hour. In a recent study, the test was able to diagnose a viral infection almost as accurately as PCR tests, which are known for their sensitivity, describes Elina Kirvesniemi/University of Helsinki . Time-Resolved Förster […]
COVID-19 - May 31, 2021
Study of Pfizer’s pneumococcal conjugate vaccine candidate + 3rd dose COVID-19 vaccine
The first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the co-administration of the company’s 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine. The primary objective in the trial is to describe safety when both vaccines are […]
COVID-19 - May 26, 2021
New trial data about BerGenBio’s bemcentinib in COVID-19 patients
The company has announced data from a Phase II trial assessing Bemcentinib in hospitalized COVID-19 patients. The trial shows that Bemcentinib has the potential to increase the rate of ventilator free survival in more than 50% of hospitalized COVID-19 patients, states the company in a press release. The trial was conducted from October 2020 across multiple […]
COVID-19 - May 25, 2021
Vaxzevria authorized for emergency use in Japan
AstraZeneca’s COVID-19 vaccine has been granted a special approval for emergency use in Japan for active immunization of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2. The Japanese Ministry of Health, Labour and Welfare granted the approval based on positive Phase III efficacy and safety data from the Oxford University-led clinical […]
COVID-19 - May 24, 2021
New report: Over NOK 3 billion for Nordic COVID-19 research
The Nordic countries combined have allocated more than NOK 3 billion for COVID-19 research reports NordForsk. The bulk of funding has targeted medical research, and Sweden is by far the largest funder, describes NordForsk in a new report. The report, compiled by NordForsk in the period February–April 2021, encompasses both ongoing and planned initiatives from […]
